APOBEC3G is the best known of several DNA cytosine deaminases that function to inhibit the replication of parasitic genetic elements including the lentivirus HIV. Several high-resolution structures of the APOBEC3G catalytic domain have been generated, but none reveal how this enzyme binds to substrate single-stranded DNA. Here, we constructed a panel of APOBEC3G amino acid substitution mutants and performed a series of biochemical, genetic, and structural assays to distinguish between “Brim” and “Kink” models for single-strand DNA binding. Each model predicts distinct sets of interactions between surface arginines and negatively charged phosphates in the DNA backbone. Concordant with both models, changing the conserved arginine at position 313 to glutamate abolished both catalytic and restriction activities. In support of the Brim model, arginine to glutamate substitutions at positions 213, 215, and 320 also compromised these APOBEC3G activities. Arginine to glutamate substitutions at Kink model residues 374 and 376 had smaller effects. These observations were supported by A3G catalytic domain-ssDNA chemical shift perturbation experiments. The overall data set is most consistent with the Brim model for single-stranded DNA binding by APOBEC3G.
References
[1]
Conticello, S.G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008, 9, 229, doi:10.1186/gb-2008-9-6-229.
[2]
LaRue, R.S.; Andresdottir, V.; Blanchard, Y.; Conticello, S.G.; Derse, D.; Emerman, M.; Greene, W.C.; Jonsson, S.R.; Landau, N.R.; Lochelt, M.; et al. Guidelines for naming nonprimate APOBEC3 genes and proteins. J. Virol. 2009, 83, 494–497.
[3]
Albin, J.S.; Harris, R.S. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert. Rev. Mol. Med. 2010, 12, e4, doi:10.1017/S1462399409001343.
[4]
Malim, M.H.; Emerman, M. HIV-1 accessory proteins—Ensuring viral survival in a hostile environment. Cell Host Microbe 2008, 3, 388–398, doi:10.1016/j.chom.2008.04.008.
[5]
Smith, J.L.; Bu, W.; Burdick, R.C.; Pathak, V.K. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends. Pharmacol. Sci. 2009, 30, 638–646, doi:10.1016/j.tips.2009.09.006.
[6]
Hultquist, J.F.; Lengyel, J.A.; Refsland, E.W.; LaRue, R.S.; Lackey, L.; Brown, W.L.; Harris, R.S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. J. Virol. 2011, 85, 11220–11234, doi:10.1128/JVI.05238-11.
[7]
Refsland, E.W.; Hultquist, J.F.; Harris, R.S. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n. PLoS Pathog. 2012. in press.
[8]
Harris, R.S.; Petersen-Mahrt, S.K.; Neuberger, M.S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell 2002, 10, 1247–1253, doi:10.1016/S1097-2765(02)00742-6.
[9]
Jarmuz, A.; Chester, A.; Bayliss, J.; Gisbourne, J.; Dunham, I.; Scott, J.; Navaratnam, N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79, 285–296.
[10]
Sheehy, A.M.; Gaddis, N.C.; Choi, J.D.; Malim, M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418, 646–650, doi:10.1038/nature00939.
Chen, K.M.; Harjes, E.; Gross, P.J.; Fahmy, A.; Lu, Y.; Shindo, K.; Harris, R.S.; Matsuo, H. Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G. Nature 2008, 452, 116–119.
[17]
Shandilya, S.M.D.; Nalam, M.N.L.; Nalivaika, E.A.; Gross, P.J.; Valesano, J.C.; Shindo, K.; Li, M.; Munson, M.; Royer, W.E.; Harjes, E.; et al. Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces. Structure 2010, 18, 28–38, doi:10.1016/j.str.2009.10.016.
[18]
Stenglein, M.D.; Matsuo, H.; Harris, R.S. Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J. Virol. 2008, 82, 9591–9599, doi:10.1128/JVI.02471-07.
[19]
Xu, H.; Svarovskaia, E.S.; Barr, R.; Zhang, Y.; Khan, M.A.; Strebel, K.; Pathak, V.K. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 5652–5657.
[20]
Navarro, F.; Bollman, B.; Chen, H.; Konig, R.; Yu, Q.; Chiles, K.; Landau, N.R. Complementary function of the two catalytic domains of APOBEC3G. Virology 2005, 333, 374–386, doi:10.1016/j.virol.2005.01.011.
[21]
Bennett, R.P.; Presnyak, V.; Wedekind, J.E.; Smith, H.C. Nuclear Exclusion of the HIV-1 host defense factor APOBEC3G requires a novel cytoplasmic retention signal and is not dependent on RNA binding. J. Biol. Chem. 2008, 283, 7320–7327.
[22]
Haché, G.; Liddament, M.T.; Harris, R.S. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain. J. Biol. Chem. 2005, 280, 10920–10924.
[23]
Iwatani, Y.; Chan, D.S.; Liu, L.; Yoshii, H.; Shibata, J.; Yamamoto, N.; Levin, J.G.; Gronenborn, A.M.; Sugiura, W. HIV-1 Vif-mediated ubiquitination/degradation of APOBEC3G involves four critical lysine residues in its C-terminal domain. Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 19539–19544.
[24]
Kohli, R.M.; Abrams, S.R.; Gajula, K.S.; Maul, R.W.; Gearhart, P.J.; Stivers, J.T. A portable hot spot recognition loop transfers sequence preferences from APOBEC family members to activation-induced cytidine deaminase. J. Biol. Chem. 2009, 284, 22898–22904.
[25]
Carpenter, M.A.; Rajagurubandara, E.; Wijesinghe, P.; Bhagwat, A.S. Determinants of sequence-specificity within human AID and APOBEC3G. DNA Repair (Amst) 2010, 9, 579–587, doi:10.1016/j.dnarep.2010.02.010.
[26]
Schumacher, A.J.; Haché, G.; MacDuff, D.A.; Brown, W.L.; Harris, R.S. The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J. Virol. 2008, 82, 2652–2660, doi:10.1128/JVI.02391-07.
[27]
Harjes, E.; Gross, P.J.; Chen, K.M.; Lu, Y.; Shindo, K.; Nowarski, R.; Gross, J.D.; Kotler, M.; Harris, R.S.; Matsuo, H. An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model. J. Mol. Biol. 2009, 389, 819–832, doi:10.1016/j.jmb.2009.04.031.
[28]
Li, M.; Shandilya, S.M.; Carpenter, M.A.; Rathore, A.; Brown, W.L.; Perkins, A.L.; Harki, D.A.; Solberg, J.; Hook, D.J.; Pandey, K.K.; et al. First-in-class small molecule inhibitors of the single-strand DNA cytosine deaminase APOBEC3G. ACS Chem. Biol. 2012, 7, 506–517, doi:10.1021/cb200440y.
[29]
Newman, E.N.; Holmes, R.K.; Craig, H.M.; Klein, K.C.; Lingappa, J.R.; Malim, M.H.; Sheehy, A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr. Biol. 2005, 15, 166–170.
[30]
Mangeat, B.; Turelli, P.; Caron, G.; Friedli, M.; Perrin, L.; Trono, D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424, 99–103.
[31]
Shindo, K.; Takaori-Kondo, A.; Kobayashi, M.; Abudu, A.; Fukunaga, K.; Uchiyama, T. The enzymatic activity of CEM15/APOBEC3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 2003, 278, 44412–44416.
[32]
Haché, G.; Shindo, K.; Albin, J.S.; Harris, R.S. Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G. Curr. Biol. 2008, 18, 819–824, doi:10.1016/j.cub.2008.04.073.
[33]
Browne, E.P.; Allers, C.; Landau, N.R. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 2009, 387, 313–321, doi:10.1016/j.virol.2009.02.026.
[34]
Miyagi, E.; Opi, S.; Takeuchi, H.; Khan, M.; Goila-Gaur, R.; Kao, S.; Strebel, K. Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1. J. Virol. 2007, 81, 13346–13353, doi:10.1128/JVI.01361-07.
[35]
Holmes, R.K.; Koning, F.A.; Bishop, K.N.; Malim, M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J. Biol. Chem. 2007, 282, 2587–2595.
Bishop, K.N.; Verma, M.; Kim, E.Y.; Wolinsky, S.M.; Malim, M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog. 2008, 4, e1000231, doi:10.1371/journal.ppat.1000231.
[38]
Yu, Q.; Konig, R.; Pillai, S.; Chiles, K.; Kearney, M.; Palmer, S.; Richman, D.; Coffin, J.M.; Landau, N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 2004, 11, 435–442.
[39]
McDougall, W.M.; Okany, C.; Smith, H.C. Deaminase activity on single-stranded DNA (ssDNA) occurs in vitro when APOBEC3G cytidine deaminase forms homotetramers and higher-order complexes. J. Biol. Chem. 2011, 286, 30655–30661.
[40]
Shlyakhtenko, L.S.; Lushnikov, A.Y.; Li, M.; Lackey, L.; Harris, R.S.; Lyubchenko, Y.L. Atomic force microscopy studies provide direct evidence for dimerization of the HIV restriction factor APOBEC3G. J. Biol. Chem. 2011, 286, 3387–3395.
[41]
Zhang, K.L.; Mangeat, B.; Ortiz, M.; Zoete, V.; Trono, D.; Telenti, A.; Michielin, O. Model structure of human APOBEC3G. PLoS One 2007, 2, e378, doi:10.1371/journal.pone.0000378.
[42]
Huthoff, H.; Autore, F.; Gallois-Montbrun, S.; Fraternali, F.; Malim, M.H. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog. 2009, 5, e1000330, doi:10.1371/journal.ppat.1000330.
[43]
Huthoff, H.; Malim, M.H. Cytidine deamination and resistance to retroviral infection: Towards a structural understanding of the APOBEC proteins. Virology 2005, 334, 147–153.
[44]
Friew, Y.N.; Boyko, V.; Hu, W.S.; Pathak, V.K. Intracellular interactions between APOBEC3G, RNA, and HIV-1 Gag: APOBEC3G multimerization is dependent on its association with RNA. Retrovirology 2009, 6, 56, doi:10.1186/1742-4690-6-56.
[45]
Opi, S.; Takeuchi, H.; Kao, S.; Khan, M.A.; Miyagi, E.; Goila-Gaur, R.; Iwatani, Y.; Levin, J.G.; Strebel, K. Monomeric APOBEC3G is catalytically active and has antiviral activity. J. Virol. 2006, 80, 4673–4682, doi:10.1128/JVI.80.10.4673-4682.2006.
[46]
Stenglein, M.D.; Harris, R.S. APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism. J. Biol. Chem. 2006, 281, 16837–16841, doi:10.1074/jbc.M602367200.
[47]
Liddament, M.T.; Brown, W.L.; Schumacher, A.J.; Harris, R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Curr. Biol. 2004, 14, 1385–1391, doi:10.1016/j.cub.2004.06.050.
[48]
Simon, J.H.; Fouchier, R.A.; Southerling, T.E.; Guerra, C.B.; Grant, C.K.; Malim, M.H. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J. Virol. 1997, 71, 5259–5267.
